Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27439104 | 0.82 | CA1 (0.48) | CA1CA2CA4GBA1FUCA1 | |
| SCHEMBL12166733 | 0.80 | CA1 (0.40) | CA1CA2CA4GBA1FUCA1 | |
| SCHEMBL23920473 | 0.79 | — | — | |
| SCHEMBL13232339 | 0.79 | — | — | |
| SCHEMBL16841460 | 0.78 | CA1 (0.39) | CA1CA2CA4 | |
| SCHEMBL16841475 | 0.78 | CA1 (0.39) | CA1CA2CA4 | |
| SCHEMBL16841459 | 0.78 | CA1 (0.39) | CA1CA2CA4 | |
| SCHEMBL598117 | 0.76 | — | — | |
| SCHEMBL4651700 | 0.76 | — | — | |
| SCHEMBL21935393 | 0.73 | CA1 (0.39) | CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| EP-2930166-B1 | METHOD FOR PREPARING 3-AMINOMETHYL-3,5,5-TRIMETHYL CYCLOHEXYLAMINE | WANHUA CHEMICAL GROUP CO LTD (CN) | 2018-06-20 | — | — | EP | disclosed |
| US-9624162-B2 | Method for preparing 3-aminomethyl-3,5,5-trimethyl cyclohexylamine | WANHUA CHEMICAL GROUP CO., LTD. (CN) | 2017-04-18 | — | — | US | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20150315133-A1 | Method For Preparing 3-Aminomethyl-3,5,5-Trimethyl Cyclohexylamine | WANHUA CHEMICAL GROUP CO., LTD. (CN) | 2015-11-05 | — | — | US | disclosed |
| EP-2930166-A1 | METHOD FOR PREPARING 3-AMINOMETHYL-3,5,5-TRIMETHYL CYCLOHEXYLAMINE | Wanhua Chemical Group Co., Ltd. (CN) | 2015-10-14 | — | — | EP | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-6828462-B2 | Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-12-07 | — | — | US | disclosed |
| EP-1442008-A1 | UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030166634-A1 | Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003040084-A1 | UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315133-A1 | Method For Preparing 3-Aminomethyl-3,5,5-Trimethyl Cyclohexylamine | INMT, ALKBH5, CA3 | CA1 87/4885CA2 761/4885CA4 431/4885 |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | ACHE, BACE1, CHRNE | CA1 161/4885CA2 1282/4885CA4 1440/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | CA1 99/4885CA2 707/4885CA4 1151/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | CA1 99/4885CA2 707/4885CA4 1151/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | CA1 126/4885CA2 1179/4885CA4 1268/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | CA1 219/4885CA2 1768/4885CA4 1969/4885 |
| US-20030166634-A1 | Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, GRIN1 | CA1 1604/4885CA2 4635/4885CA4 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.